Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Share-based Compensation (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Share-based Compensation readings, the most recent being $20.1 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 28.6% to $20.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $92.4 million, a 8.88% decrease, with the full-year FY2025 number at $92.4 million, down 8.88% from a year prior.
  • Share-based Compensation hit $20.1 million in Q4 2025 for Tandem Diabetes Care, down from $21.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $28.2 million in Q4 2024 to a low of $12.9 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $21.6 million (2023), compared with a mean of $21.4 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 42.94% in 2022 and later decreased 28.6% in 2025.
  • Tandem Diabetes Care's Share-based Compensation stood at $17.1 million in 2021, then soared by 42.94% to $24.4 million in 2022, then dropped by 6.96% to $22.7 million in 2023, then grew by 23.86% to $28.2 million in 2024, then dropped by 28.6% to $20.1 million in 2025.
  • The last three reported values for Share-based Compensation were $20.1 million (Q4 2025), $21.1 million (Q3 2025), and $25.6 million (Q2 2025) per Business Quant data.